Notice

mylife Diabetescare is no longer part of the Ypsomed Group. Click here to visit the website.

  • English
  • German
  • 中文
Skip navigation
  • Media
  • Investors
 
Logo
Skip navigation
  • Our products
    • Product finder
    • Pen injectors
      • UnoPen
      • ServoPen
      • YpsoPen
      • YpsoFlow
      • FixPen
      • LyoTwist
      • VarioJect
    • Autoinjectors
      • YpsoLoop
      • YpsoMate
      • YpsoMate 2.25
      • YpsoMate 5.5
      • SmartPilot for YpsoMate
      • CliniPilot
      • VarioJect
    • Wearable injectors
      • YpsoDose
    • Digital Health
      • Therapy management
      • Connected devices
      • Resources
    • Innovation Hub
      • YpsoDot
      • YpsoGoFlex
      • YpsoGoEco
    Spotlight

    Good solutions come full circle

    Discover YpsoLoop
  • Our expertise
    • Track record
    • Modular platforms
      • Platform development
      • Customization process
      • Scalability
    • Manufacturing
      • Precision tooling
      • Injection molding
      • Assembly
    • Partner network
      • Final assembly services
      • Final assembly equipment
      • Packaging and labeling equipment
      • Device testing equipment
    • Services
      • Human factors
      • Regulatory
      • Intellectual property
      • Testing & design verification
      • Quality
      • Sustainability services
    Spotlight

    We act reliably and in a solution-oriented manner.

    Read story
  • News & insights
    • Product news
    • Company stories
    • Press releases
    • Blog
    • Events
    • Resources
    Spotlight

    Ypsomed to establish first U.S. manufacturing facility

    Read news
  • Careers
    • Working in Switzerland
      • Professionals
      • Young professionals
      • Open jobs
    • Working in Germany
      • Open jobs
  • About us
    • Management
    • Corporate strategy
    • Sustainability
    • Global presence
    • History
    • Suppliers
  • Contact
 
  • English
  • German
  • 中文
Skip navigation
  • Media
  • Investors
 
Skip navigation
  • Our products
    • Product finder
    • Pen injectors
      • UnoPen
      • ServoPen
      • YpsoPen
      • YpsoFlow
      • FixPen
      • LyoTwist
      • VarioJect
    • Autoinjectors
      • YpsoLoop
      • YpsoMate
      • YpsoMate 2.25
      • YpsoMate 5.5
      • SmartPilot for YpsoMate
      • CliniPilot
      • VarioJect
    • Wearable injectors
      • YpsoDose
    • Digital Health
      • Therapy management
      • Connected devices
      • Resources
    • Innovation Hub
      • YpsoDot
      • YpsoGoFlex
      • YpsoGoEco
    Spotlight

    Good solutions come full circle

    Discover YpsoLoop
  • Our expertise
    • Track record
    • Modular platforms
      • Platform development
      • Customization process
      • Scalability
    • Manufacturing
      • Precision tooling
      • Injection molding
      • Assembly
    • Partner network
      • Final assembly services
      • Final assembly equipment
      • Packaging and labeling equipment
      • Device testing equipment
    • Services
      • Human factors
      • Regulatory
      • Intellectual property
      • Testing & design verification
      • Quality
      • Sustainability services
    Spotlight

    We act reliably and in a solution-oriented manner.

    Read story
  • News & insights
    • Product news
    • Company stories
    • Press releases
    • Blog
    • Events
    • Resources
    Spotlight

    Ypsomed to establish first U.S. manufacturing facility

    Read news
  • Careers
    • Working in Switzerland
      • Professionals
      • Young professionals
      • Open jobs
    • Working in Germany
      • Open jobs
  • About us
    • Management
    • Corporate strategy
    • Sustainability
    • Global presence
    • History
    • Suppliers
  • Contact
 

Financial calendar

  • Investors
  • Financial calendar
  • Event detail

Media and Analyst Conference for the 2024/25 half-year results

13.11.2024 10:00am - 11:30am Virtual

Annual Report and Fact Sheet

  • Ypsomed Semiannual Report 2024/25 (636.1 KiB)
  • Financial key figures half-year 2024/25 (85.3 KiB)

Press release as PDF

  • Ypsomed significantly increases sales and decides to initiate the sale of Diabetes Care (108.0 KiB)
  • Video statement semiannual results 2024/25

Presentation

  • Presentation of Half-Year Results 2024/25 (7.2 MiB)
Sam Ghezelbash
Head of Investor Relations and M&A
Ypsomed Holding AG
Brunnmattstrasse 6
3401 Burgdorf
Switzerland
sam.ghezelbash@ypsomed.com
+41 76 228 51 45

Go Back

Sam Ghezelbash
Head of Investor Relations and M&A
Ypsomed Holding AG
Brunnmattstrasse 6
3401 Burgdorf
Switzerland
sam.ghezelbash@ypsomed.com
+41 76 228 51 45
TOP
Quick links
Skip navigation
  • Our products
  • Our expertise
  • About us
  • Sustainability
  • Investors
  • Media
  • Careers
  • Ypsomed Test Community
 
Legal & compliance
Skip navigation
  • Imprint
  • Terms of service
  • Data privacy and cookie policy
  • Certificates
  • Vulnerability disclosure
 
Resources & information
Skip navigation
  • Suppliers
  • Search
  • Sitemap
 
Contact

Ypsomed AG
Headquarters Burgdorf
Brunnmattstrasse 6
3401 Burgdorf
Switzerland

T +41 (0)34 424 41 11
F +41 (0)34 424 41 22
info@ypsomed.com

Subscribe to our newsletter

Follow us on
Page last update: 16.10.2025 - 3:24pm © by Ypsomed
Ypsomed Logo